<< Exhibitor
<< Press release
On June 4 2025, Elsevier officially released the 2024 CiteScore, a key metric used to assess the impact of academic journals. VIEW, jointly sponsored by China Professional Community of Experimental Medicine (CPCEM) and published by John Wiley & Sons, achieved a CiteScore of 14.5 for 2024.
From 18-22 May 2025, Brussels, Belgium, hosted the 26th IFCC-EFLM EUROMEDLAB Congress of Clinical Chemistry and Laboratory Medicine and the 49th Annual Meeting of the Royal Belgian Society of Laboratory Medicine.
The 22nd China International In Vitro Diagnostics Expo by CACLP and the 5th China IVD Supply Chain Expo (CISCE) took place from 22–24 March 2025 in Hangzhou, achieving unprecedented scale and impact.
With just two weeks to go, anticipation is building for the 22nd China International In Vitro Diagnostic Expo by CACLP, the largest and most influential gathering of the IVD industry in China! Taking place 22-24 March 2025, at the Hangzhou Grand Convention & Exhibition Center, CACLP 2025 promises to be a world-class showcase of the latest innovations, professional networking and business opportunities.
The 7th China IVD Distribution Enterprise Forum is set to take place on 23 March 2025, at the Hangzhou Grand Convention and Exhibition Center.
As China’s in vitro diagnostic (IVD) industry continues its rapid development, numerous outstanding enterprises have made remarkable achievements in research and development, production, and market expansion.
Welcome to the 22nd China International In Vitro Diagnostic Expo by CACLP & 5th China IVD Supply Chain Expo!
The 1st National Primary Healthcare Laboratory Forum is a key event focused on strengthening primary healthcare laboratory testing, which plays a vital role in early disease diagnosis and treatment outcomes.
As China’s pet market continues to flourish, with rising pet ownership and increasing per capita spending, the demand for quality veterinary care is rapidly growing.
The 10th China Experimental Medicine Conference is set to take place on 21-23 March 2025, at the Hangzhou Grand Convention and Exhibition Center.
<< Industry news
The TOBY Test has received breakthrough device designation from the FDA for the early detection of bladder cancer. This designation underscores the significant potential of this innovative urine-based assay to fundamentally alter the landscape of bladder cancer detection and surveillance, offering a much-needed non-invasive alternative to current diagnostic paradigms.
Merck, a leading science and technology company, today announced that it has closed the acquisition of SpringWorks Therapeutics, Inc., for an enterprise value of $3.4 billion (approximately €3 billion)*, following regulatory clearances and the fulfillment of other customary closing conditions.
Molecular diagnosis is performed at the gene level with nucleic acids as the object for detection, with high sensitivity and accuracy.
Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.
PathAI, a global leader in artificial intelligence (AI) and digital pathology solutions, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for AISight® Dx*—its digital pathology image management system—for use in primary diagnosis in clinical settings. Building on the initial 510(k) clearance for AISight Dx(Novo) in 2022, this latest milestone underscores the platform’s continuous innovation and PathAI’s commitment to delivering enhanced capabilities as the product evolves.
Microsoft has built an artificial intelligence-powered medical tool it claims is four times more successful than human doctors at diagnosing complex ailments, as the tech giant unveils research it believes could speed up treatment.
MGI Tech Co., Ltd. (MGI), a company dedicated to developing core tools and technologies that drive innovation in life sciences, today announced a partnership with Negedia, an initiative born from Fondazione Telethon to expand access to DNBSEQ™-powered genomic sequencing and Stereo-seq spatial transcriptomics for precision medicine and biomedical research in Italy.
RetinalGenix Technologies Inc. OTCQB:RTGN (“RetinalGenix” or the “Company”), a pioneering developmental-stage company focused on ophthalmic screening, monitoring, pharmacogenetic mapping, and repurposed drug development for early detection and treatment of eye and systemic diseases, has entered into an agreement with LabCorp, one of the nation’s largest laboratory services organizations, to support the rollout of the RetinalGenix DNA/RNA/GPS Pharmaco-Genetic Mapping™ platform. This innovative program enables patients to undergo genetic testing and high-resolution retinal imaging anonymously and provide insights into both ocular and systemic diseases.
Sysmex America, Inc., a leading diagnostic solutions company offering hematology, hemostasis, urinalysis, flow cytometry and informatic solutions, has received FDA clearance for the CN-6000™ Automated Blood Coagulation Analyzer. This clearance includes the reagent products used in five commonly performed hemostasis tests:
Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced it has received World Health Organization (WHO) approval for the offshored and outsourced upstream manufacturing activities of its high-volume TrinScreen™ HIV rapid test, a cornerstone diagnostic product used in HIV screening programs. This regulatory approval marks a critical milestone in the Company’s comprehensive transformation plan aimed at restoring financial performance and driving sustainable profitability.
<< Video showcase
CACLP 2025 onsite - The Convergence of Laboratory Medicine and In Vitro Diagnostics
The 12th China IVD Industry Development Conference (CIIDC)
The 10th China Experimental Medicine Conference (CEMC)
International Laboratory Medicine and In Vitro Diagnostic Forum
The 11th China IVD Industry Development Conference (CIIDC)
The 9th China Experimental Medicine Conference (CEMC)
CACLP 2024 onsite - The Convergence of Laboratory Medicine and In Vitro Diagnostics
CACLP APP is available for download now!
Gentian at CACLP 2023 Onsite
in.vent Diagnostics at CACLP 2023 Onsite
Charming Group at CACLP 2023 Onsite
Dialab at CACLP 2023 Onsite
JTC at CACLP 2023 Onsite
Certest at CACLP 2023 Onsite
Yashraj Biotechnology at CACLP 2023 Onsite
Magtivio at CACLP 2023 Onsite
The 8th China Experimental Medicine Conference (CEMC)
The 10th China IVD Industry Development Conference (CIIDC)
CACLP 2023 onsite - The Convergence of Laboratory Medicine and In Vitro Diagnostics
CACLP's new website is launching!
<< Download centre
CACLP 2025 Post-show Press Release
CACLP 2025 Exhibitor Manual
CACLP 2025 Floor Plan
CACLP 2025 Full Schedule
CACLP & CISCE 2024 Draw Global Attention to Innovations and Collaborations in IVD Industry
CACLP & CISCE to present the latest in IVD with 1300+ Exhibitors and 100+ Concurrent Activities this March in Chongqing.pdf
CACLP & CISCE 2024 - Floor Plan
CACLP & CISCE 2024 - Exhibitor Manual
1200+ Global Exhibitors Confirmed Their Participation on the 21st CACLP and 4th CISCE in Chongqing, March 2024
CACLP & CISCE 2023 Post-show Report
Copyright © 2025 GL events Ruihe (Shanghai) Exhibition Co., Ltd. All Rights Reserved. ( 沪ICP备12004745号-1 )
We deliver the latest IVD news straight to your inbox. Stay in touch with CACLP News.
sign-up for our newsletter today.
To ensure our newsletter hit your inbox, make sure to add @caclp.com to your safe senders list. And, as always, feel free to contact
us with any questions and thanks again for subscribing.
Go back
